vs
Side-by-side financial comparison of Nano Dimension Ltd. (NNDM) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.
Nano Dimension Ltd. is the larger business by last-quarter revenue ($57.8M vs $57.6M, roughly 1.0× Phathom Pharmaceuticals, Inc.). Nano Dimension Ltd. produced more free cash flow last quarter ($-21.1M vs $-167.0M).
Nano Dimension Ltd. is a leading provider of additively manufactured electronics solutions and 3D printing technologies. It designs high-precision 3D printers, related materials, and software for producing printed circuit boards, microelectronics components, and multi-layer electronic devices, serving aerospace, defense, medical, automotive, and industrial electronics segments across global markets.
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
NNDM vs PHAT — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.8M | $57.6M |
| Net Profit | $-98.8M | — |
| Gross Margin | 43.1% | 86.7% |
| Operating Margin | -155.1% | — |
| Net Margin | -171.1% | — |
| Revenue YoY | — | 94.1% |
| Net Profit YoY | — | 71.6% |
| EPS (diluted) | $-0.45 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $57.6M | ||
| Q3 25 | — | $49.5M | ||
| Q2 25 | — | $39.5M | ||
| Q1 25 | — | $28.5M | ||
| Q4 24 | $57.8M | $29.7M | ||
| Q3 24 | — | $16.4M | ||
| Q2 24 | $28.4M | $7.3M | ||
| Q2 23 | $29.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-30.0M | ||
| Q2 25 | — | $-75.8M | ||
| Q1 25 | — | $-94.3M | ||
| Q4 24 | $-98.8M | — | ||
| Q3 24 | — | $-85.6M | ||
| Q2 24 | $-79.2M | $-91.4M | ||
| Q2 23 | $12.6M | — |
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 87.5% | ||
| Q2 25 | — | 87.2% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | 43.1% | 87.1% | ||
| Q3 24 | — | 85.6% | ||
| Q2 24 | 45.8% | 81.2% | ||
| Q2 23 | 44.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -30.8% | ||
| Q2 25 | — | -151.7% | ||
| Q1 25 | — | -276.5% | ||
| Q4 24 | -155.1% | — | ||
| Q3 24 | — | -433.0% | ||
| Q2 24 | — | -1055.4% | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -60.5% | ||
| Q2 25 | — | -191.9% | ||
| Q1 25 | — | -330.7% | ||
| Q4 24 | -171.1% | — | ||
| Q3 24 | — | -523.3% | ||
| Q2 24 | -279.4% | -1248.6% | ||
| Q2 23 | 42.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.41 | ||
| Q2 25 | — | $-1.05 | ||
| Q1 25 | — | $-1.31 | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | — | $-1.32 | ||
| Q2 24 | $-0.35 | $-1.56 | ||
| Q2 23 | $0.05 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $317.2M | $130.0M |
| Total DebtLower is stronger | — | $209.1M |
| Stockholders' EquityBook value | $860.0M | $-438.2M |
| Total Assets | $902.5M | $259.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $130.0M | ||
| Q3 25 | — | $135.2M | ||
| Q2 25 | — | $149.6M | ||
| Q1 25 | — | $212.3M | ||
| Q4 24 | $317.2M | $297.3M | ||
| Q3 24 | — | $334.7M | ||
| Q2 24 | $231.8M | $276.2M | ||
| Q2 23 | $454.6M | — |
| Q4 25 | — | $209.1M | ||
| Q3 25 | — | $207.1M | ||
| Q2 25 | — | $205.1M | ||
| Q1 25 | — | $203.2M | ||
| Q4 24 | — | $201.4M | ||
| Q3 24 | — | $175.7M | ||
| Q2 24 | — | $174.4M | ||
| Q2 23 | — | — |
| Q4 25 | — | $-438.2M | ||
| Q3 25 | — | $-422.5M | ||
| Q2 25 | — | $-405.8M | ||
| Q1 25 | — | $-338.4M | ||
| Q4 24 | $860.0M | $-253.6M | ||
| Q3 24 | — | $-187.1M | ||
| Q2 24 | $870.3M | $-233.8M | ||
| Q2 23 | $1.1B | — |
| Q4 25 | — | $259.1M | ||
| Q3 25 | — | $240.3M | ||
| Q2 25 | — | $250.2M | ||
| Q1 25 | — | $294.2M | ||
| Q4 24 | $902.5M | $378.3M | ||
| Q3 24 | — | $387.0M | ||
| Q2 24 | $911.0M | $319.4M | ||
| Q2 23 | $1.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.9M | $-166.8M |
| Free Cash FlowOCF − Capex | $-21.1M | $-167.0M |
| FCF MarginFCF / Revenue | -36.5% | -290.0% |
| Capex IntensityCapex / Revenue | 3.8% | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-328.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-166.8M | ||
| Q3 25 | — | $-14.1M | ||
| Q2 25 | — | $-62.7M | ||
| Q1 25 | — | $-84.9M | ||
| Q4 24 | $-18.9M | $-266.8M | ||
| Q3 24 | — | $-63.6M | ||
| Q2 24 | $-30.7M | $-70.7M | ||
| Q2 23 | $-56.1M | — |
| Q4 25 | — | $-167.0M | ||
| Q3 25 | — | $-14.1M | ||
| Q2 25 | — | $-62.8M | ||
| Q1 25 | — | $-84.9M | ||
| Q4 24 | $-21.1M | $-266.9M | ||
| Q3 24 | — | $-63.6M | ||
| Q2 24 | — | $-70.8M | ||
| Q2 23 | — | — |
| Q4 25 | — | -290.0% | ||
| Q3 25 | — | -28.6% | ||
| Q2 25 | — | -159.0% | ||
| Q1 25 | — | -297.9% | ||
| Q4 24 | -36.5% | -899.8% | ||
| Q3 24 | — | -389.0% | ||
| Q2 24 | — | -966.2% | ||
| Q2 23 | — | — |
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | 3.8% | 0.5% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.6% | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | -4.47× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
